Abstract：Objective To investigate the efficacy of Duvalizumab combined with Etoposide Capsules in the treatment of recurrent extensive small cell lung cancer.Methods A total of forty patients with recurrent extensive small cell lung cancer admitted to Yichun People's Hospital from January 2021 to December 2022 were selected as the study subjects.They were divided into control group and observation group by random number table method,with 20 cases in each group.The control group patients were treated with Etoposide Capsules,while the observation group patients were treated with Duvalizumab combined with Etoposide Capsules.The clinical efficacy,changes in serum neuron-specific enolase(NSE)levels before and after chemotherapy,adverse reactions during treatment and long-term survival were compared between the two groups.Results The objective response rate and disease control rate of the observation group were higher than those of the control group,with statistically significant differences (P＜0.05).The serum NSE level in the observation group after chemotherapy was lower than that in the control group,with statistically significant difference(P＜0.05).There were no statistically significant differences in the incidence and severity of adverse reactions such as leukopenia,thrombocytopenia,neutropenia,gastrointestinal reactions,liver and kidney damage between the two groups during the treatment period(P＞0.05).The observation group had longer progression free survival and overall survival compared to the control group,with statistically significant difference (P＜0.05).Conclusion The combination of Duvalizumab and Etoposide Capsules has a significantly improved therapeutic effect on recurrent extensive small cell lung cancer compared to the use of Etoposide Capsules alone.It can significantly prolong the survival time of patients without significantly increasing adverse reactions,and is worthy of clinical recommendation.
Karmakar A，Kumtakar A，Sehgal H，et al.Interobserver Variation in Response Evaluation Criteria in Solid Tumors 1.1[J].Acad Radiol，2019，26（4）：489-501.
[6]
Basch E，Becker C，Rogak LJ，et al.Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events（PRO-CTCAE）[J].Clin Trials，2021，18（1）：104-114.
京公网安备 11010502046607号